iData Insights

Ulcerative Colitis - Pipeline Review, H2 2015 Now Available at iData Insights

News   •   Jan 30, 2016 12:06 IST

This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ulcerative Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ulcerative Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179089/ulcerative-colitis-pipeline-review-h2-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179089/ulcerative-colitis-pipeline-review-h2-2015

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Ulcerative Colitis Overview 12

Therapeutics Development 13

Pipeline Products for Ulcerative Colitis - Overview 13

Pipeline Products for Ulcerative Colitis - Comparative Analysis 14

Ulcerative Colitis - Therapeutics under Development by Companies 15

Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 22

Ulcerative Colitis - Pipeline Products Glance 23

Late Stage Products 23

Clinical Stage Products 24

Early Stage Products 25

Unknown Stage Products 26

Ulcerative Colitis - Products under Development by Companies 27

Ulcerative Colitis - Products under Investigation by Universities/Institutes 32

Ulcerative Colitis - Companies Involved in Therapeutics Development 33

4D Pharma Plc 33

Advinus Therapeutics Ltd. 34

Ajinomoto Pharmaceuticals Co., Ltd. 35

Altheus Therapeutics, Inc. 36

Am-Pharma B.V. 37

Amgen Inc. 38

Arena Pharmaceuticals, Inc. 39

Astellas Pharma Inc. 40

Atlantic Healthcare Plc 41

Avaxia Biologics, Inc. 42

BioAtla, LLC 43

BioLineRx, Ltd. 44

Bionovis SA 45

Celgene Corporation 46

Cellceutix Corporation 47

Celltrion, Inc. 48

ChemoCentryx, Inc. 49

ChironWells GmbH 50

Chong Kun Dang Pharmaceutical Corp. 51

Cosmo Pharmaceuticals S.p.A 52

Dr. Falk Pharma GmbH 53

Effimune SAS 54

Eli Lilly and Company 55

Emergent BioSolutions Inc. 56

Enceladus Pharmaceuticals BV 57

enGene, Inc 58

Enterome Bioscience SA 59

Epirus Biopharmaceuticals, Inc. 60

Flexion Therapeutics, Inc. 61

Galapagos NV 62

Genentech, Inc. 63

Genor BioPharma Co., Ltd. 64

Gilead Sciences, Inc. 65

GW Pharmaceuticals Plc 66

Hetero Drugs Limited 67

iCo Therapeutics Inc. 68

Idera Pharmaceuticals, Inc. 69

InDex Pharmaceuticals AB 70

Innovate Biopharmaceuticals, Inc. 71

INOXIA Lifesciences GmbH 72

Intas Pharmaceuticals Ltd. 73

Invion Limited 74

Johnson & Johnson 75

Kaken Pharmaceutical Co., Ltd. 76

Kymab Limited 77

LIPID THERAPEUTICS GmbH 78

LTT Bio-Pharma Co., Ltd. 79

Mabion SA 80

Mabtech Limited 81

Medestea Research & Production S.p.A. 82

Momenta Pharmaceuticals, Inc. 83

Morphotek, Inc. 84

Mycenax Biotech Inc. 85

Oncobiologics, Inc. 86

Pfizer Inc. 87

Pluristem Therapeutics Inc. 88

ProtAb Ltd 89

Protagonist Therapeutics Inc. 90

Qu Biologics Inc. 91

Rebiotix Inc. 92

Receptos, Inc. 93

Sandoz International GmbH 94

Seres Therapeutics, Inc. 95

Sigmoid Pharma Limited 96

Stelic Institute & Co. 97

sterna biologicals Gmbh & Co KG 98

Synergy Pharmaceuticals, Inc. 99

Takeda Pharmaceutical Company Limited 100

Therapeutic Proteins International, LLC 101

Therapix Biosciences Ltd 102

Theravance Biopharma, Inc. 103

Tillotts Pharma AG 104

Trino Therapeutics Limited 105

Ventria Bioscience 106

Zyngenia, Inc. 107

Ulcerative Colitis - Therapeutics Assessment 108

Assessment by Monotherapy Products 108

Assessment by Combination Products 109

Assessment by Target 110

Assessment by Mechanism of Action 115

Assessment by Route of Administration 119

Assessment by Molecule Type 121

Drug Profiles 123

(mesalamine + N-acetylcysteine) - Drug Profile 123

abrilumab - Drug Profile 125

ABS-11 - Drug Profile 126

adalimumab biosimilar - Drug Profile 127

adalimumab biosimilar - Drug Profile 128

adalimumab biosimilar - Drug Profile 129

adalimumab biosimilar - Drug Profile 130

adalimumab biosimilar - Drug Profile 131

adalimumab biosimilar - Drug Profile 132

adalimumab biosimilar - Drug Profile 133

adalimumab biosimilar - Drug Profile 134

adalimumab biosimilar - Drug Profile 135

adalimumab biosimilar - Drug Profile 136

adalimumab biosimilar - Drug Profile 137

adalimumab biosimilar - Drug Profile 138

adalimumab biosimilar - Drug Profile 139

AJM-300 - Drug Profile 140

AKP-11 - Drug Profile 142

alicaforsen sodium - Drug Profile 144

Anatabine - Drug Profile 145

Antisense RNAi Oligonucleotide to Inhibit microRNA-214 for Ulcerative Colitis and Colon Cancer - Drug Profile 147

APD-334 - Drug Profile 148

apremilast - Drug Profile 149

ASP-3291 - Drug Profile 152

AVX-470 - Drug Profile 153

AW/EPO-002 - Drug Profile 155

AW/EPO-003 - Drug Profile 156

AW/EPOPD-01 - Drug Profile 157

AW/EPOPD-02 - Drug Profile 158

AW/EPOPD-06 - Drug Profile 159

bertilimumab - Drug Profile 160

BL-7040 - Drug Profile 162

brilacidin tetrahydrochloride - Drug Profile 164

budesonide - Drug Profile 166

CCX-507 - Drug Profile 169

CKD-506 - Drug Profile 170

cyclosporine CR - Drug Profile 171

D-9030 - Drug Profile 172

DIMS-0150 - Drug Profile 173

dolcanatide - Drug Profile 176

Drug to Inhibit Phospholipase A2 for Crohn's Disease and Ulcerative Colitis - Drug Profile 177

Drugs for Ulcerative Colitis - Drug Profile 178

EB-120 - Drug Profile 179

EFFI-7H - Drug Profile 180

EG-10 - Drug Profile 181

EG-12 - Drug Profile 182

enalaprilat - Drug Profile 183

ES-210 - Drug Profile 184

Read More http://www.idatainsights.com/reports-landing-page.php?id=179089/ulcerative-colitis-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.